AstraZeneca (United Kingdom)

A little-known perspective on the I-squared statistic

The I-squared statistic has become hugely popular in meta-analysis. Motivated by the recent statement that 'Informally, it can be considered to reflect the extent to which confidence intervals displayed in a forest plot do not overlap with each other', this short note formalises...

B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study

B7-H4 is a promising antibody-drug conjugate (ADC) target with high expression in several solid tumors and limited expression in normal tissue. B7-H4 negatively regulates T-cell function, and high expression of B7-H4 is associated with disease progression. AZD8205 (puxitatug samr...

Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study

Abstract Background Subcutaneous oncology monoclonal antibodies (SCOmAbs) offer significant benefits compared to intravenous formulations, including reduced administration time and potential for self-administration. However, little has been published on real-world preparation and...

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

BackgroundThe standard of care for patients with muscle-invasive bladder cancer continues to evolve. Whether perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin is effective in such patients is unknown. MethodsIn this phase 3 open-label tri...

Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity

Abstract Heterobifunctional targeted degraders (HBDs) enable potent removal of protein targets but their clinical success can be hindered by de novo toxicity inherent to their bivalent chemistry. Here we introduce a drug discovery framework that exploits high-throughput proteomic...

Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca

Biocatalysis is becoming a strategic manufacturing capability at AstraZeneca, enabling selective transformations under milder conditions and with the potential to reduce waste and resource intensity relative to conventional routes. This review summarizes how AstraZeneca is embedd...

Tozorakimab to Prevent COPD Exacerbations

BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations despite receiving standard-of-care inhaled maintenance therapy. Dysregulated interleukin-33 signaling is implicated in the pathogenesis of COPD. Tozorakimab is a monoclonal antibody tha...

Live Attenuated Influenza Vaccine (LAIV) for Children for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

Both inactivated influenza vaccine and live attenuated influenza vaccine (LAIV) (indicated for use in children aged 2–17 years) effectively prevent influenza transmission and related outcomes. Despite high transmission among children, vaccination practices in Sweden focus primari...

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics

Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...